Cantargia
David Liberg is the current VP of Cancer Research at Cantargia. Prior to this, they were Head of the Section for Cell Biology and Biochemistry at Active Biotech from 2006 to 2015. David has also been a Post Doctoral Scientist at Clinical Sciences Centre MRC UK and Lund University. Their research has primarily been in epigenetics and lymphocyte development.
David Liberg has a PhD in Immunology and a Molecular Biology from Lund University.
Their manager is Göran Forsberg, CEO . David Liberg works with Lars Thorsson - VP Clinical Development , Bengt Jöndell - CFO, and Ignacio Garcia-Ribas - CMO.
This person is not in any offices
Cantargia
1 followers
Cantargia utvecklar en antikroppsbaserad behandling riktad mot målmolekylen IL1RAP som har potential att användas för ett flertal olika cancersjukdomar.